The S-1/A with firm pricing range signals the IPO is progressing toward effectiveness, likely within weeks. Watch for Nasdaq listing approval (required condition to close), final pricing, and any material business updates before the roadshow. Post-IPO, the primary catalyst will be the Phase 2b EMERGE trial initiation for PBH. The $7.17 per share dilution to new investors (69% of offering price) is substantial but typical for a pre-revenue biotech IPO.
Executive Summary
Vogenx filed Amendment No. 1 to its S-1 registration statement, setting the IPO at 6,250,000 shares priced between $11.00-$13.00 per share (midpoint $12.00) for listing on Nasdaq under VOGX. The clinical-stage biopharma focused on its SGLT1 inhibitor mizagliflozin for post-bariatric hypoglycemia and gastroparesis expects net proceeds of ~$67.8M, extending runway through 2028, though significant additional capital will be needed for Phase 3 trials. This amendment finalizes offering size and price range after the prior S-1 filed 14 days ago.
Key Financial Metrics
Key Facts
- Offering 6,250,000 shares at $11.00-$13.00 per share; midpoint $12.00
- Estimated net proceeds of ~$67.8M ($78.2M if underwriters exercise 937,500-share option in full)
- Pro forma post-IPO shares outstanding: 13,905,643 (14,843,143 with overallotment)
- No product revenue; net loss of $475K in Q1 2026 and $1.4M in FY2025
- Cash of $251K as of March 31, 2026; IPO funds expected to support operations through 2028
- Lead candidate mizagliflozin (SGLT1 inhibitor) targets PBH, gastroparesis, and GIP-dependent Cushing's Syndrome
- Phase 2b EMERGE study for PBH expected to begin screening in 2026
- Material weaknesses in internal control over financial reporting identified
- IPO proceeds allocated: ~$26.3M for mizagliflozin PBH, ~$20.4M for gastroparesis, ~$844K for accrued expenses
- Reverse stock split 1-for-3 effected July 28, 2026 prior to this filing
Financial Impact
$67.8M gross IPO proceeds expected at midpoint, adding ~$68M in pro forma as-adjusted cash from $251K current balance
Risk Factors
- No approved products; pre-revenue with no path to near-term profitability
- Lead mizagliflozin remains in early-stage development; Phase 3 costs are unfunded by IPO proceeds
- Competitor Amylyx has Phase 3 PBH data expected 2026, potentially eroding first-mover advantage
- Material weaknesses in internal controls could delay SEC reporting post-IPO
- Dependence on Kissei license agreement for core mizagliflozin technology
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001185185-26-003162 |
| Document: vogenxex10-3.htm | 0001185185-26-003162 |
| Document: vogenxex1-1.htm | 0001185185-26-003162 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $17.56 | awaiting T+20 | — | $17.34 (−1.25%) |
Aug 17, 2026 10w ago | Press Release | $15.75 $32.21 | ▲ +104.51% | ▲ +106.49% | $17.34 (+10.10%) |
Aug 11, 2026 10w ago | 3 | $13.00 $29.86 | ▲ +129.69% | ▲ +131.59% | $17.34 (+33.38%) |
Aug 11, 2026 10w ago | 3 | $13.00 $29.86 | ▲ +129.69% | ▲ +131.59% | $17.34 (+33.38%) |
Aug 10, 2026 11w ago | S-1/A | — | awaiting T+20 | — | — |
Jul 29, 2026 12w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers